Roche Partners With UCB On Anti-Tau Alzheimer’s Drug

 
• By Joseph Haas

UCB gets $120m up front from Roche for option rights to UCB0107 and retains full rights to the drug in progressive supranuclear palsy.

Alzheimers_677117191_Atthapon-Raksthaput_1200.jpg
Roche takes another shot in Alzheimer's by licensing UCB anti-tau candidate

More from Deals

More from Business